Dr. Anthony B. El-Khoueiry MD Medical Oncologist

Dr. Anthony El-Khoueiry is a medical oncologist in Los Angeles, California. He is affiliated with multiple hospitals in the area, including Keck Hospital of USC and University of Southern California-Norris Cancer Hospital. He received his medical degree from Keck School of Medicine of USC and has been in practice for 12 years. Dr. El-Khoueiry accepts several types of health insurance, listed below. He is one of 13 doctors at Keck Hospital of USC and one of 7 at University of Southern California-Norris Cancer Hospital who specialize in Medical Oncology.

Are you Dr. Anthony El-Khoueiry? Claim your profile to make edits or add details. Edit Profile

Office Location

See Contact Information

Specialty & Clinical Interests

Medical Oncologist: Gastrointestinal Cancer

Hospital Affiliation

Keck Hospital of USC
High performing in Cancer

University of Southern California-Norris Cancer Hospital
Ranked #48 in Cancer

Education & Medical Training

University of Southern California/LAC+USC Medical Center
Residency, Internal Medicine, 1998 - 2001

University of Southern California/LAC+USC Medical Center
Fellowship, Medical Oncology, 2001 - 2002

University of Southern California/LAC+USC Medical Center
Fellowship, Hematology, 2002 - 2003

University of Southern California/LAC+USC Medical Center
Fellowship, Medical Oncology, 2003 - 2004

Keck School of Medicine of USC
Class of 1998

Certifications & Licensure

American Board of Internal Medicine
Certified 13 years in Internal Medicine

American Board of Internal Medicine
Certified 10 years in Medical Oncology

CA State Medical License
Active through 2014

Publications & Presentations

The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry, A.,Posey, J. A.,Castillo Ferrando, J. R.,Krishnamurthi, S. S.,Syed, S.,Kollia, G.,Walters, I.,Fischer, B. S.,Masson, E.

Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
Pohl, A.,El-Khoueiry, A.,Yang, D.,Zhang, W.,Lurje, G.,Ning, Y.,Winder, T.,Hu-Lieskoven, S.,Iqbal, S.,Danenberg, K. D.,Kahn, M.,Teo, J. L.,Shriki, J.,Stebbing, J.,Lenz, H. J.

First-in-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients with Advanced Hepatocellular Carcinoma.
Zhu, A. X.,Gold, P. J.,El-Khoueiry, A. B.,Abrams, T. A.,Morikawa, H.,Ohishi, N.,Ohtomo, T.,Philip, P. A.

See all 10 publications

Insurances Accepted

  • Aetna Choice POS II
  • Aetna HMO
  • Anthem KeyCare PPO
  • BCBS Blue Card PPO
  • BCBS Illinois PPO
  • Blue Shield California PPO
  • CIGNA HMO
  • CIGNA Open Access
  • CIGNA PPO
  • First Health PPO
  • Great West PPO
  • Health Net California Large Group PPO
  • Humana ChoiceCare Network PPO
  • Multiplan PHCS PPO
  • Multiplan PHCS PPO - Kaiser
  • Multiplan PPO
  • United Healthcare - Direct Choice Plus POS
  • United Healthcare - Direct Options PPO
Find More Doctors
Doctor Finder

Our Doctor Finder includes most U.S. physicians. Doctors are not ranked, learn more.

Browse Doctors by

Specialty

Location

Search all Doctors

Profiles by Doximity

Your Message Has Been Submitted

As part of our research on the correction you submitted, you may be contacted at the email address provided.

Sorry, Your Message Could Not Be Submitted

Please try again later, or E-mail your message to doctors@usnews.com and include the Web address (URL) of the page that contains incorrect information.